Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-25T18:07:12.871Z Has data issue: false hasContentIssue false
  • English
  • Français

Moclobemide Versus Clomipramine in Endogenous Depression

A Double-Blind Randomised Clinical Trial

Published online by Cambridge University Press:  02 January 2018

J. D. Guelfi ,
C. Payan ,
J. Fermanian ,
A. M. Pedarriosse  and
R. Manfredi
J. D. Guelfi
Affiliation:
Ste-Anne Hospital (Pr Samuel-Lajeunesse Department), 100 rue de la Santé, 75674 Paris, Cedex 14, France
C. Payan
Affiliation:
Biostatistics Department, Necker Hospital, Paris
J. Fermanian
Affiliation:
Necker Hospital, Paris
A. M. Pedarriosse
Affiliation:
Produits Roche, Neuilly sur Seine, France
R. Manfredi
Affiliation:
Produits Roche, Neuilly sur Seine, France
Get access Rights & Permissions [Opens in a new window]

Abstract

The effects of moclobemide (300–600 mg/day), a reversible monoamine oxidase inhibitor – A (MAOI-A), were compared in a double-blind, multi-centre trial with those of clomipramine (100–200 mg/day) on 129 in-patients suffering from endogenous depression (according to ICD–9 and the Newcastle Scale). No significant differences in efficacy were seen between the two treatment groups. In the moclobemide group the mean scores on the MADRS were 36.4 on day 0 and 13.2 on day 42 (end-point analysis); scores were 37.4 and 10.9 respectively in the clomipramine group. An earlier onset of antidepressant activity was noted for moclobemide. Tolerability was significantly better for moclobemide, as shown by the Clinical Global Impression of Tolerance (CGIT). Anticholinergic effects, weight gain and orthostatic hypotension were more frequent in the clomipramine group. No biological treatment-related changes were observed.

Type
Papers
Information
The British Journal of Psychiatry , Volume 160 , Issue 4 , April 1992 , pp. 519 - 524
Copyright
Copyright © Royal College of Psychiatrists, 1992 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). Washington, DC: APA.Google Scholar
Andreasen, N. C., Grove, W. M. & Maurer, R. (1980) Cluster analysis and the classification of depression. British Journal of Psychiatry, 137, 256–265.CrossRefGoogle ScholarPubMed
Andreasen, N. C., Scheftner, W., Reich, T., et al (1986) The validation of the concept of endogenous depression. Archives of General Psychiatry, 43, 246–251.CrossRefGoogle ScholarPubMed
Baumhackl, U., Biziere, K., Fischbach, R., et al (1989) Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM–III): An Austrian double-blind, multi-centre study. British Journal of Psychiatry, 155 (suppl. 6), 78–83.Google Scholar
Blackwell, B., Marley, E., Price, J., et al (1967) Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. British Journal of Psychiatry, 113, 349–365.CrossRefGoogle ScholarPubMed
Berlin, I., Zimmer, R., Cournot, A., et al (1989) Determination and comparison of the pressor effect of tyramine during long term moclobemide and tranylcypromine treatment in healthy volunteers. Clinical Pharmacology and Therapeutics, 46, 344–351.CrossRefGoogle ScholarPubMed
British Medical Research Council (1965) Clinical trial of the treatment of depressive illness. British Medical Journal, i, 881–886.Google Scholar
Burkard, W. P., Bonetti, E. P., Da Prada, M., et al (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics, 248, 391–399.Google ScholarPubMed
Casacchia, M., Carolei, A., Barba, C., et al (1984) A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Pharmacopsychiatry, 17, 122–125.Google Scholar
Commission of the European Communities (1989) Guidelines of the Quality, Safety and Efficacy of Medicinal Products for Human Use, no. 3, pp. 210 211 Brussels: CEC.Google Scholar
Da Prada, M., Kettler, R., Keller, H. H., et al (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics, 248, 401–414.Google Scholar
Derogatis, L. R. (1977) SCL 90–R: Administration, Scoring and Procedure. Manual I. Baltimore, MD: Johns Hopkins.Google Scholar
Dixon, W. J. (1985) BMDP Statistical Software. Berkeley: University of California Press.Google Scholar
Guelfi, J. D., Pull, C. B., Guelfi, C., et al (1983) La CHESS, utilisation dans la pathologic anxieuse et depressive. Structure factorielle. Annates Médico-psychologiques, 141, 257–278.Google Scholar
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.CrossRefGoogle ScholarPubMed
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278–296.Google Scholar
Hollister, L. E. (1977) Individualised dosage of tricyclic antidepressants. Drugs, 14, 161–162.CrossRefGoogle ScholarPubMed
Larsen, J. K., Holm, P. & Mikkelsen, P. L. (1984) Moclobemide and clomipramine in the treatment of depression. Acta Psychiatrica Scandinavica, 70, 254–260.CrossRefGoogle ScholarPubMed
Montgomery, S. A. & Asberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382–389.Google Scholar
Norman, T. R., Ames, D., Burrows, G. D., et al (1985) A controlled study of a specific MAO-A reversible inhibitor (Ro 11–1163) and amitriptyline in depressive illness. Journal of Affective Disorders, 8, 29–35.Google Scholar
Pariente, P., Lepine, J. P., Boulenger, J. P., et al (1989) The Symptom Check-List 90R (SCL-90R) in a French general psychiatric 708 outpatient sample: is there a factor structure? Psychiatry and Psychobiology, 4, 151–157.Google Scholar
Paykel, E. S. & White, J. L. (1989) A European study of views on the use of monoamine oxidase inhibitors. British Journal of Psychiatry, 155 (suppl. 6), 9–17.CrossRefGoogle Scholar
Puech, A. J. & Berlin, I. (1990) Moclobemide: Drug and Alcohol Interactions. Kyoto: CINP Congress.Google Scholar
Roth, M., Gurney, C. & Mountjoy, C. G. (1983) The Newcastle rating scales. Acta Psychiatrica Scandinavica (suppl. 310), 42–54.Google Scholar
Stefanis, C. N., Alevizos, B. & Papadimitriou, G. (1984) Moclobemide (Ro 11–1163) versus desipramine: a double-blind study in depressive patients. In Monoamine Oxidase and Disease, Prospects for Therapy with Reversible Inhibitors, London: Academic Press.Google Scholar
Versiani, M., Oggero, U., Alterwain, P., et al (1989) A double-blind comparative trial of moclobemide versus imipramine and placebo in major depressive episodes. British Journal of Psychiatry, 155 (suppl. 6), 72–77.Google Scholar
Winer, B. J. (1971) Statistical Principles in Experimental Design (2nd edn). New York: McGraw-Hill.Google Scholar
World Health Organization (1978) Mental Disorders: Glossary and Guide to their Classification in Accordance with the Ninth Revision of the International Classification of Diseases (ICD-9). Geneva: WHO.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.